Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

Lexcol Aug. 5 at 7:27 PM

$CMPX $AZN $BMY

0 · Reply

Top_Dog_Pro_Trader Aug. 5 at 4:33 PM

$BMY How you make $. Market cries like a baby that there is no deal, even though it wasn’t in the share price. Earnings and forecasts were beats with PT’s $70+. So when the baby is crying, buy/add some shares on these emotions…lol!

0 · Reply

StocktwitsNews Aug. 5 at 4:17 PM

AstraZeneca-Bristol Myers’ $400B Merger Buzz Cools After Report Denies Talks – ‘There Never Was A Deal To Be Done’ $AZN $BMY https://stocktwits.com/news/equity/markets/astra-zeneca-bristol-myers-400-b-merger-buzz-cools-after-report-denies-talks-there-never-was-a-deal-to-be-done/cZo4wlORJec

0 · Reply

itsphd Aug. 5 at 2:45 PM

$ABVX I'm thinking people thought there was going to be MA news after $AZN squashed the rumor that they were buying $BMY

0 · Reply

Alphasearch Aug. 5 at 2:30 PM

$BMY Whoever started the merger rumors needs to go to jail. Holding

0 · Reply

HostileTakeovers Aug. 5 at 2:20 PM

$BMY

0 · Reply

notreload_ai Aug. 5 at 1:44 PM

Senior source tells Reuters there are no talks between $AZN and $BMY, ending $400B merger rumors and lifting shares. https://notreload.xyz/xy/no-azn-bmy-deal/

0 · Reply

Top_Dog_Pro_Trader Aug. 5 at 1:42 PM

$BMY comical, typical hissy fit on news that the AZN merger was false…lol! And people sell, even though post earnings this was a no-brainer to go to $70 … lol! The merger IMO is a diversion from the forecasts and upcoming significant catalysts! Looks like they are ahead of the patent cliff bot mantra that mindlessly keeps getting posted here…comical!

0 · Reply

alvicryptz Aug. 5 at 1:13 PM

$SDGR Collaboration with $BMY https://finance.yahoo.com/technology/ai/articles/schr-dinger-announces-strategic-collaboration-123000698.html

0 · Reply

scdtrader213 Aug. 5 at 1:08 PM

$BMY $AZN shares fell 1.4% in premarket trading after a Reuters report said AstraZeneca was not in talks with the drugmaker over a potential deal, dashing recent merger speculation. Citing a senior source close to the matter, Reuters reported there was “no deal” between the companies, adding that no discussions had taken place. AstraZeneca shares rose 5.6% following the report.

0 · Reply

Market Cap	133.74B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	10.03
Forward PE	9.49
Profit Margin	14.64%
Debt to Equity Ratio	1.93

Volume	14,099,934
Avg Vol	13,122,856
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	71%
Beta	0.22
Analysts	Sell
Price Target	$64.50